<DOC>
	<DOC>NCT00987727</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of OPTIVEÂ® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.</brief_summary>
	<brief_title>Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Have been using artificial tears for at least 3 months prior to study inclusion Have been using preservative free artificial tears at least three times daily (TIB) for at least 2 weeks immediately prior to study inclusion Having moderate to severe symptoms suggestive of dry eye Current enrollment in an investigational drug or device study or participation in such a study within 3 months prior to entry into this study Moderate to severe blepharitis History or active signs of ocular trauma, ocular infection, or ocular inflammation within the last 3 months History or active signs of ocular allergic disease or ocular herpes within the last year History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>